Head-to-head · WeighScore
Gala Health vs Shapely
The verdict
Gala Health takes it — 82.9/100 to 65.4/100.
Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A compounded tirzepatide and semaglutide program for women that reaches all 50 states and keeps a brand-name Ozempic path open — but its $179 and $149 headline rates are yearly-subscription prices, not monthly ones.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Gala Health | Shapely |
|---|---|---|
| WeighScore | 82.9/100 | 65.4/100 |
| Grade | B− | C |
| Scorecard rank | #17 | #220 |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | $179/mo (yearly subscription) | Not disclosed |
| Coverage | All 50 states | 4 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #17 · B−
Strengths
- Low compounded entry if you prepay the year — $179/mo tirzepatide and $149/mo microdose on the yearly subscription, $199/mo on a 3-month plan
- Prices are published openly rather than quiz-gated, with all doses included at the one rate
- All 50 states and LegitScript-verified, with a brand-name Ozempic path kept open ($1,299)
- HRT and menopause care available alongside GLP-1
Where it loses points
- No month-to-month price is published anywhere — the $179 tirzepatide and $149 microdose rates are both yearly subscriptions, and the shortest term Gala names is a 3-month plan at $199/mo
- Compounded formulations are not FDA-approved
- Brand-name Ozempic is priced steeply at $1,299
- No oral or sublingual route offered yet — injection only
- Newer operator (Gala GLP-1 by AI Coaching Inc) with no named clinicians and no named dispensing pharmacy
Graded #220 · C
Strengths
- Founded by Dr. Justin Zaghi, MD/MBA — Harvard-trained, board-certified in internal medicine and obesity medicine, with Medical Director Ana Lisa
- Brand-name GLP-1s (Wegovy, Ozempic, Zepbound, Mounjaro, Foundayo) covered by major PPO and Medicare at copay
- Compounded semaglutide from $99/month with free 2-day shipping, syringes, and supplies included via 503A/503B pharmacy
- 1:1 registered dietitian (RDN) and monthly video provider visits included in every plan; unlimited chat and app support
- Cellular smart scale provided to qualifying patients for ongoing weight tracking throughout the program
Where it loses points
- Currently available only in California, Florida, New York, and Texas — 46 states unserved despite announced expansion
- Telehealth subscription ($99/mo self-pay, $49 first-month promo) is charged separately from compounded medication cost
- Labs not included — $75 flat rate for uninsured patients; baseline bloodwork may be required before prescribing
- No LegitScript certification found on any public page
- Compounding pharmacy partner not named publicly; 503A/503B status claimed but specific pharmacy undisclosed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.